Visus Therapeutics Inc., A Clinical Stage Biopharmaceutical Company Focused On Developing Multi-Targeted Treatments For The Eye, Today Announced It Has Expanded Its Pipeline Via The Acquisition Of All Patents And Other Assets Of Viewpoint Therapeutics, Inc. (
